OBJECTIVE: To compare survival and cause specific mortality in @entity101 @entity1 with non- @entity101 @entity1 derived from the same random population, and to study mortality and morbidity from @entity65 in the @entity101 @entity1 in relation to effects on cardiovascular risk factors during 22-23 years of follow up. DESIGN: Prospective, population based observational study. SUBJECTS AND METHODS: 686 @entity101 @entity1 aged 47-55 at screening compared with 6810 non- @entity101 @entity1 . The @entity101 @entity1 were having stepped care treatment with either beta adrenergic blocking drugs, @entity2740 diuretics, or combination treatment. Mortality, morbidity, and adverse effects were registered at yearly examinations and from death certificates. MAIN OUTCOME MEASURES: All cause mortality and cause specific mortality. RESULTS: Treated @entity101 @entity1 had significantly impaired probability of total survival as well as survival from @entity301 and @entity64 . All cause mortality as well as @entity301 and @entity64 mortality were very similar in @entity101 @entity1 and normotensive @entity1 during the first decade, but increased steadily thereafter despite continuous good blood pressure control. Smoking, signs of target organ damage, and high serum @entity165 levels, but not blood pressure at screening, were significantly related to the incidence of @entity301 during follow up. In time dependent Cox's regression analysis, the incidence of @entity301 was significantly related only to serum @entity165 concentrations in the study. @entity5 mortality was almost similar in treated @entity101 @entity1 (61/686, 8.9%) and non- @entity101 @entity1 (732/6810, 10.8%). CONCLUSION: Treated @entity101 @entity1 had impaired survival and increased mortality from @entity65 compared with non- @entity101 @entity1 of similar age. These differences were observed during the second decade of follow up. During an observation period of 22-23 years-about 15 000 @entity1 years- @entity101 @entity1 receiving diuretics and beta blockers had no increased risk of @entity5 or @entity65 .

Survival in treated XXXX : follow up study after two decades.

@entity1 :: ('9606', 'Species') :: ['patient', 'men'] @entity64 :: ('MESH:D020521', 'Disease') :: ['stroke'] @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertensive'] @entity301 :: ('MESH:D003327', 'Disease') :: ['coronary heart disease'] @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer', 'Cancer'] @entity2740 :: ('CHEBI:50264', 'Chemical') :: ['thiazide'] @entity65 :: ('MESH:D002318', 'Disease') :: ['non-cardiovascular disease', 'cardiovascular disease', 'cardiovascular diseases'] @entity165 :: ('MESH:D002784', 'Chemical') :: ['cholesterol']
@entity101 :: (MESH:D006973,Disease) :: ['hypertension']
